Literature DB >> 1459581

Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2.

S Alberti1, S Miotti, M Stella, C E Klein, M Fornaro, S Menard, M I Colnaghi.   

Abstract

Trop-2 is a cell surface structure recognized by the 162-46.2 mAb and expressed by most human carcinomas. Since the 162-46.2 mAb works poorly in immunoprecipitation, to characterize the structure of Trop-2 we searched for other mAbs directed against this molecule. Selection of candidates was performed by analyzing the characteristics of mAbs directed against epithelial cells and by comparing the staining pattern of each mAb with the one of the 162-46.2 on frozen sections of human epidermis. Two mAbs, T16 and MOv-16, were selected for further analysis. Formal proof that candidate mAbs reacted with Trop-2 was obtained by comparing their binding patterns to mouse L cells transfected with the Trop-2 gene by genomic DNA transfection and selected by FACS using the FITC-162-46.2 mAb. In immunofluorescence FACS analysis the FITC-T16 and FITC-MOv-16 mAbs specifically stained Trop-2 transfectants. The specificity of binding was confirmed by selective blocking of the staining by the respective unconjugated mAb. Interestingly, cross-blocking studies indicated that the 162-46.2, T16 and MOv-16 mAbs recognize the same epitope or closely spaced ones on the Trop-2 molecule. T16 and MOv-16 efficiently immunoprecipitate Trop-2 from Trop-2 transfectants and from the human cell line OVCA-432, indicating that it is a cell surface glycoprotein, with an apparent molecular weight of 57 kD in non-reducing conditions. A weaker band of 38 kD is often co-precipitated with the 57 kD form in an apparently specific manner.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459581     DOI: 10.1089/hyb.1992.11.539

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  20 in total

1.  Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Natalia Buza; Sergio Pecorelli; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2011-07-13       Impact factor: 8.661

2.  Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7: implications in the pathogenesis of gelatinous drop-like corneal dystrophy.

Authors:  Mina Nakatsukasa; Satoshi Kawasaki; Kenta Yamasaki; Hideki Fukuoka; Akira Matsuda; Motokazu Tsujikawa; Hidetoshi Tanioka; Maho Nagata-Takaoka; Junji Hamuro; Shigeru Kinoshita
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Marta Bellone; Paola Todeschini; Luisa Carrara; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2011-03-30       Impact factor: 5.482

4.  Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.

Authors:  Lara P Stepan; Esther S Trueblood; Kari Hale; John Babcook; Luis Borges; Claire L Sutherland
Journal:  J Histochem Cytochem       Date:  2011-05-06       Impact factor: 2.479

5.  Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.

Authors:  Eliana Bignotti; Antonella Ravaggi; Chiara Romani; Marcella Falchetti; Silvia Lonardi; Fabio Facchetti; Sergio Pecorelli; Joyce Varughese; Emiliano Cocco; Stefania Bellone; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Int J Gynecol Cancer       Date:  2011-12       Impact factor: 3.437

6.  Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; Paola Todeschini; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

7.  Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.

Authors:  Jing Zhu; Wenwen Wu; Yukiko Togashi; Naoe Taira Nihira; Yoshikazu Johmura; Dajiang Zhu; Makoto Nakanishi; Yasuo Miyoshi; Tomohiko Ohta
Journal:  Breast Cancer       Date:  2022-07-27       Impact factor: 3.307

8.  Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.

Authors:  Y J Fang; Z H Lu; G Q Wang; Z Z Pan; Z W Zhou; J P Yun; M F Zhang; D S Wan
Journal:  Int J Colorectal Dis       Date:  2009-05-07       Impact factor: 2.571

9.  DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene.

Authors:  S Alberti; M Nutini; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

10.  Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.

Authors:  Eliana Bignotti; Laura Zanotti; Stefano Calza; Marcella Falchetti; Silvia Lonardi; Antonella Ravaggi; Chiara Romani; Paola Todeschini; Elisabetta Bandiera; Renata A Tassi; Fabio Facchetti; Enrico Sartori; Sergio Pecorelli; Dana M Roque; Alessandro D Santin
Journal:  BMC Clin Pathol       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.